Working… Menu

Immediate Treatment vs Colposcopic Follow-up for Biopsy-Proven CIN 1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00156026
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : January 29, 2009
Canadian Institutes of Health Research (CIHR)
Information provided by:
Ontario Clinical Oncology Group (OCOG)

Brief Summary:
This study looks at immediate treatment of a cervix with CIN 1 versus regular six-month follow-up with colposcopy and treatment if CIN 1 progresses.

Condition or disease Intervention/treatment Phase
Cervical Intraepithelial Neoplasia Procedure: loop electrosurgical excision procedure (LEEP) Phase 3

Detailed Description:
In women who present with biopsy-proven CIN 1, to compare the management approach of regular colposcopic follow-up and only treating progressive disease using the LEEP, with an approach of immediate treatment using LEEP. The primary outcome is progression to more advanced disease (i.e., CIN 2, CIN 3 or cancer).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 415 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Trial of Immediate Treatment vs. Colposcopic Follow-up for Biopsy-Proven CIN 1
Study Start Date : November 2000
Actual Primary Completion Date : September 2007
Actual Study Completion Date : September 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Biopsy

Arm Intervention/treatment
Experimental: 1
Immediate Treatment - LEEP - Loop electrosurgical excision procedure
Procedure: loop electrosurgical excision procedure (LEEP)
1. loop electrosurgical excision procedure

No Intervention: 2
Colposcopic Follow-up

Primary Outcome Measures :
  1. progression to more advanced disease [ Time Frame: 18 months ]

Secondary Outcome Measures :
  1. persistent CIN 1 after 18 months [ Time Frame: 18 months ]
  2. bleeding. [ Time Frame: 18 months ]
  3. predict disease persistence or progression [ Time Frame: 18 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Eligible patients will:

    • have documented CIN 1 by histologic assessment as the highest grade lesion present,
    • have the lesion confined to the cervix and completely visualized,
    • be 16 years or older.

Exclusion Criteria:

  • any one of the following will be an excluding characteristic:

    • index Pap smear showing CIN 2, CIN 3 or cancer;
    • index Pap smear shows atypical glandular cells of unknown significance, glandular dysplasia, or malignancy requiring immediate investigation;
    • patients with previously identified CIN 1 by biopsy who are already in a colposcopic surveillance program;
    • unsatisfactory colposcopic exam defined as inability to see the extent of the lesion in the endocervical canal or absence of a lesion on the ectocervix but endocervical curettage shows CIN 1;
    • pregnancy;
    • prior therapy for dysplasia including medical (5FU), surgical (Laser, LEEP) or cryotherapy;
    • prior gynecologic cancer;
    • prior pelvic radiation therapy;
    • inability to attend outpatient follow-up visits because of geographic inaccessibility;
    • other malignancies except non-melanoma skin cancer;
    • immunosuppression due to diseases such as AIDS, organ transplantation, or on immunosuppressive medications such as prednisone, imuran or chemotherapy for diseases like systemic lupus;
    • cognitively impaired or otherwise unable to obtain written informed consent;
    • extension of the CIN 1 lesion to vagina or a separate vaginal lesion showing dysplasia;
    • colposcopically visible condyloma outside of the transformation zone;
    • known allergy to local analgesics;
    • clinically evident vaginitis must be treated and resolved prior to entry on the trial;
    • inability to read and respond in English/French;
    • failure to provide informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00156026

Layout table for location information
Universidade Estadual de Campinas
Campinas, Brazil, CEP 13083-970
Instituto Fernandes Figueira - Oswaldo Cruz Foundation
Rio de Janeiro, Brazil, CEP 22250-020
Canada, British Columbia
B.C. Cancer Agency
Vancouver, British Columbia, Canada, V5Z 4E6
Canada, Nova Scotia
Nova Scotia Cancer Centre
Halifax, Nova Scotia, Canada, B3H 1V7
Canada, Ontario
Brantford General Hospital
Brantford, Ontario, Canada, N3T 3J2
Hamilton Health Sciences - Henderson Site
Hamilton, Ontario, Canada, L8P 3A9
London Health Sciences Centre
London, Ontario, Canada, N6A 4G5
St. Michael's Hospital
Toronto, Ontario, Canada, M5B 1W8
Canada, Saskatchewan
University of Saskatchewan
Saskatoon, Saskatchewan, Canada, S7K 3H3
Hôpital du Saint-Sacrement
Quebec, Canada, G1S 2L6
Sponsors and Collaborators
Ontario Clinical Oncology Group (OCOG)
Canadian Institutes of Health Research (CIHR)
Layout table for investigator information
Study Chair: Laurie Elit, MD Juravinski Cancer Centre
Principal Investigator: Mark Levine, MD Ontario Clinical Oncology Group (OCOG)
Principal Investigator: Jim Julian, MMath McMaster University, Dept of Clinical Epidemiology & Biostatistics
Layout table for additonal information
Responsible Party: Dr. Mark Levine, Ontario Clinical Oncology Group Identifier: NCT00156026    
Other Study ID Numbers: OCOG-2000-CIN1
First Posted: September 12, 2005    Key Record Dates
Last Update Posted: January 29, 2009
Last Verified: January 2009
Keywords provided by Ontario Clinical Oncology Group (OCOG):
cervical intraepithelial neoplasia
loop electrosurgical excision procedure
expectant management
human papilloma virus
Additional relevant MeSH terms:
Layout table for MeSH terms
Cervical Intraepithelial Neoplasia
Carcinoma in Situ
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type